-
公开(公告)号：EP0138948B1
公开(公告)日：1989-02-01
申请号：EP84901477.4
申请日：1984-03-05
申请人： CETUS CORPORATION
发明人： CHANG, Shing
CPC分类号： C07K14/61 , C07K14/55 , C07K2319/02 , C07K2319/034 , C07K2319/036 , C07K2319/75 , C12N15/10 , C12N15/625 , Y10S930/30
摘要： Modified signal peptides derived from wild-type signal peptides of the type that are capable of forming membrane-bound lipoproteins and methods for making such modified signal peptides and DNA sequences encoding them. Modified signal peptides of the invention and DNA sequences encoding them are useful for increasing the secretion of heterologous gene products produced by transformed host organisms. The invention further discloses a method for producing recombinant DNA sequences in vivo.
-
102.发明公开Plasminogen activators, DNA encoding the same and their preparation and use 失效PLASMINOGEN激活剂，编码它们的DNA及其制备和使用
公开(公告)号：EP0273774A3
公开(公告)日：1988-12-14
申请号：EP87311532
申请日：1987-12-30
申请人： CETUS CORPORATION
CPC分类号： C12N9/6456
摘要： Novel plasminogen activators are disclosed. Of the novel plasminogen activators, one is a modified urokinase that is altered to make it less susceptible to forming two chain-urokinase and to increase the fibrin specificity of urokinase. Also among the novel plasminogen activators are fibrinolytic proteins comprised of at least one domain capable of interacting with fibrin and the protease domain of urokinase. The domain capable of interacting with fibrin may have an amino acid sequences substantially the same as those of kringle-2 of t-PA, kringle-1 and/or -4 of plasminogen and the finger domain of t-PA. The protease domain may have an amino acid sequence substantially the same as that of 30 Kd urokinase. DNA sequences encoding the novel plasminogen activators, expression vectors and expression systems therefor are also disclosed and claimed.
-
103.发明授权Partition proficiency encoded DNA and plasmids incorporating the same for transforming gram-positive organisms 失效符合条件的编码DNA和等离子体同时进行转化成功的有机体
公开(公告)号：EP0095947B1
公开(公告)日：1988-11-30
申请号：EP83303195.8
申请日：1983-06-02
申请人： CETUS CORPORATION
发明人： Chang, Shing
-
104.发明公开Oxidation resistant IL-2 muteins and their production, formulations containing such muteins, and DNA sequences and expression vectors coding for such muteins and corresponding transformed host cells 失效耐氧化IL-2和它们的生产方法，含有此类制剂的制剂，以及DNA序列和表达载体的编码，用于这些宿主和相应的转化的宿主细胞
公开(公告)号：EP0200280A3
公开(公告)日：1988-08-24
申请号：EP86200766
申请日：1986-01-17
申请人： CETUS CORPORATION
CPC分类号： C07K14/55
摘要： A biologically active reference (e.g. human) IL-2 (interleukin-2) protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionine residue susceptible to chloramine T or peroxide oxidation and wherein additional, non-susceptible methionine residues are not so substituted.
-
公开(公告)号：EP0273778A2
公开(公告)日：1988-07-06
申请号：EP87311552.1
申请日：1987-12-31
申请人： CETUS CORPORATION
发明人： Warren, Mary Kim , Ralph, Peter
CPC分类号： C07K14/53 , A61K38/00 , C07K14/535
摘要： Two colony stimulating factors, G-CSF and CSF-1, are synergistic in their effect on colony formation and stimulation of the immune system.
摘要翻译： 两种集落刺激因子G-CSF和CSF-1在其对集落形成和免疫系统刺激的作用上具有协同作用。
-
106.发明公开Plasminogen activators, DNA encoding the same and their preparation and use 失效Plasminogenaktivatoren，dafürkodierende DNS，ihre Herstellung und Anwendung。
公开(公告)号：EP0273774A2
公开(公告)日：1988-07-06
申请号：EP87311532.3
申请日：1987-12-30
申请人： CETUS CORPORATION
CPC分类号： C12N9/6456
摘要： Novel plasminogen activators are disclosed. Of the novel plasminogen activators, one is a modified urokinase that is altered to make it less susceptible to forming two chain-urokinase and to increase the fibrin specificity of urokinase. Also among the novel plasminogen activators are fibrinolytic proteins comprised of at least one domain capable of interacting with fibrin and the protease domain of urokinase. The domain capable of interacting with fibrin may have an amino acid sequences substantially the same as those of kringle-2 of t-PA, kringle-1 and/or -4 of plasminogen and the finger domain of t-PA. The protease domain may have an amino acid sequence substantially the same as that of 30 Kd urokinase. DNA sequences encoding the novel plasminogen activators, expression vectors and expression systems therefor are also disclosed and claimed.
摘要翻译： 公开了新型纤溶酶原激活剂。 在新型纤溶酶原激活剂中，一种是改变的尿激酶，其被改变以使其不易形成两种尿链激酶，并增加尿激酶的纤维蛋白特异性。 新型纤溶酶原激活剂之一也是由至少一个能够与纤维蛋白相互作用的结构域和尿激酶蛋白酶结构域组成的纤维蛋白溶解性蛋白质。 能够与纤维蛋白相互作用的结构域可以具有与纤溶酶原的t-PA，kringle-1和/或-4以及t-PA的手指结构域的kringle-2基本相同的氨基酸序列。 蛋白酶结构域可以具有与30Kd尿激酶基本相同的氨基酸序列。 还公开并要求保护编码新型纤溶酶原激活剂的DNA序列，表达载体及其表达系统。
-
公开(公告)号：EP0226419A3
公开(公告)日：1988-04-20
申请号：EP86309516
申请日：1986-12-05
申请人： CETUS CORPORATION , THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary Department of Commerce
发明人： Bjorn, Michael Jon , Fitzgerald, David , Frankel, Arthur Edward , Laird, Walter Joseph , Pastan, Ira , Ring, David Barratt , Willingham, Mark , Winkelhake, Jeffrey
IPC分类号： A61K47/00 , A61K39/395 , A61K37/02
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6869 , Y10S424/804 , Y10S424/807 , Y10S514/885 , Y10S530/808 , Y10S530/864
摘要： Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID 50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.
-
公开(公告)号：EP0175360A3
公开(公告)日：1988-03-30
申请号：EP85111823
申请日：1985-09-18
申请人： CETUS CORPORATION
IPC分类号： C07K15/00 , G01N33/574 , C07K07/08
CPC分类号： C07K14/82 , A61K38/00 , G01N33/531 , Y10S435/81 , Y10S435/961 , Y10S436/808 , Y10S436/813
摘要： Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipiated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.
-
109.发明公开Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations 失效组合物和使用白介素-2和/或干扰素-β和肿瘤坏死因子的组合治疗或用于药物或制剂的制备。
公开(公告)号：EP0248516A1
公开(公告)日：1987-12-09
申请号：EP87303120.7
申请日：1987-04-09
申请人： CETUS CORPORATION
CPC分类号： A61K38/2013 , A61K38/215 , A61K38/191 , A61K2300/00
摘要： Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-β, or of TNF, IL-2 and IFN-β in combination. The composition of TNF and IL-2 and/or IFN-p may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, and lymphoma.
摘要翻译： 在哺乳动物中的抗肿瘤活性可以通过给予所述哺乳动物宿主协同有效量的TNF和IL-2的TNF或IFN和-β来增强，或TNF，IL-2和ITN的β组合。 TNF和IL-2和/或IFN-β的组合物可在体外制备或单独地施用给宿主。 如果TNF和IL-2被依次施用，所述TNF必须在IL-2之前给药以获得协同作用。 该组合物用于治疗如检查肥大细胞瘤，黑色素瘤，白血病，和淋巴瘤的癌症。
-
110.发明授权Method for producing vicinal, heterogeneous dihalogenated products, their use, and novel products 失效用于生产维生素，异构二糖产品，其使用和新产品的方法
-
-
-
-
-
-
-
-
-
搜索结果
225 条记录 (耗时 0.019 秒)
